Press Releases

TomoTherapy® System Provides Favorable Cosmetic Outcomes Without Compromising Efficacy in Low-Risk Breast Cancer Patients SUNNYVALE, Calif., July 21, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System. The study, published in the June issue of the peer-reviewed AntiCancer Research, International Journal of Cancer Research and Treatment, reported no recurrence of cancer in the treated breast at median follow-up of 34 months. Additionally, more than 95 percent of patients and their physicians rated cosmesis -- preservation of the normal appearance of the breast -- as good/excellent. Read More »
Accuray Products Continue to Receive Highest Composite User Satisfaction Ratings in Latest MD Buyline Report SUNNYVALE, Calif., July 14, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems continue to set the standard for overall user satisfaction. The Accuray systems received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., according to the Q2 2016 MD Buyline Market Intelligence Briefing™. The most recent ratings trend also shows Accuray has achieved the highest ratings among industry peers over the past three years. Read More »
Accuray to Report Fiscal 2016 Fourth Quarter And Full Year Results On August 17, 2016 SUNNYVALE, CALIF., July 7, 2016—Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal fourth quarter and full year ended June 30, 2016 on Wednesday, August 17, 2016 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day. Read More »
Accuray Receives 510(k) FDA Clearance for the Radixact™ Image-Guided Radiation Therapy Platform and Integrated Software SUNNYVALE, Calif., June 27, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact™ Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. These next generation hardware and software solutions which, together, make up the new Radixact system, enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients, including those undergoing retreatment. The new Radixact system represents a major step forward in the evolution of the TomoTherapy® System in treatment speed and ease of use. Read More »
FUCAM Treats 1,000 Breast Cancer Patients with the TomoTherapy® System SUNNYVALE, Calif., June 21, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today that the Fundación de Cancer de Mama in México City (FUCAM) has treated 1,000 breast cancer patients with the TomoTherapy® System. The milestone was achieved less than 18 months after the center installed the technology, underscoring its value as a mainstream treatment option to maximize tumor control with low toxicities for the full range of breast cancer cases, from routine to complex. Read More »
United Kingdom’s NHS Supply Chain to Acquire Seven TomoTherapy® Systems SUNNYVALE, Calif., June 16, 2016 – Accuray Incorporated (NASDAQ: ARAY) has a signed deal with NHS Supply Chain for seven TomoTherapy® Systems in a new partnership designed to provide clinicians and their patients with additional access to advanced radiation therapy. This deal was entered into backlog during Accuray's fourth fiscal quarter. This deal with NHS Supply Chain further increases the reach and accessibility of the TomoTherapy System to a wider number of NHS hospitals who wish to make this technology available for the full range of cancer patients. Read More »
Accuray to Participate in the 2016 Jefferies Healthcare Conference SUNNYVALE, Calif., May 25, 2016-- Accuray Incorporated (NASDAQ: ARAY), announced today that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference in New York, NY on Friday, June 10, 2016 at 8:00 a.m. ET. Read More »
Accuray to Host Analyst and Investor Day on May 20, 2016 SUNNYVALE, Calif., May 19, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Analyst and Investor Day on Friday, May 20, 2016 at the Lotte Palace Hotel in New York City. Read More »

Pages